

Supplementary Material

Safety and Tolerability of a 90-minute Infusion of Sandoz Biosimilar Rituximab in B-cell lymphoproliferative disorders in a real-world setting. Muntañola A et al.

1. Supplementary tables.....	2
------------------------------	---

Table S1. Patients by center.

Center	N	%
Hospital 12 de Octubre	6	4.8
Complejo Asistencial de Ávila	20	16.1
Hospital Universitario de Navarra	21	16.9
Hospital del Mar	25	20.2
Hospital Marqués de Valdecilla	16	12,9
Hospital Universitario Mutua de Terrassa	22	17.7
Hospital Universitario Valle de Hebrón	14	11.3
<i>Total</i>	<i>124</i>	<i>100.0</i>

Table S2. List of schedules using SDZ-RTX according to the number of rapid infusion.

Number rapid infusion	1	2	3	4	5	6	7	8	9	10	11	Total
R maintenance	5	4	4	6	8	9	9	5	4	2	1	57
R monotherapy	14	15	14	3	1	2	1					50
R-CHOP/similar	60	60	53	48	33	4	2					260
R-CVP	3	3	3	3	2							14
R-Bendamustine	18	17	16	15	12	1	2	1	1	1		84
R-Chlorambucil	1	1	1	1	1							5
R-Venetoclax	8	8	6	5	5							32
R-Gemcitabine/R-GEMOX	11	10	8	9	7	2	2	1	1	1	1	53
R-Lenalidomide	1	1	1	1	1							5
R-ESHAP	1	1	1									3
R-others	2	1	1	2	2	3	2	2	1	1	1	18
Total	124	121	108	88	72	21	18	9	7	5	3	576